Biofrontera Inc. (BFRI)
NASDAQ
Closed
Aug 24, 2026
Day's Range
1.4152 wk Range
0.5550Overview - BFRI - Biofrontera Inc.
Key Statistics
Valuation
Enterprise Value
24.81M
P/E (Trailing)
‪0.88‬
P/E (Forward)
‪3.51‬
PEG Ratio
‪-0.06‬
Price / Sales (TTM)
‪0.48‬
Price / Book
‪3.60‬
EV / EBITDA
‪-4.15‬
Profitability
Gross Margin
‪79.01%‬
Profit Margin
‪-13.78%‬
Operating Margin
‪-4.36%‬
Return on Assets
‪-17.45%‬
Return on Equity
‪-988.35%‬
Ownership
Shares Outstanding
11.87M
Float
11.83M
Short % of Shares Outstanding
‪0.50%‬
Held by Insiders
‪11.99%‬
Held by Institutions
‪20.71%‬
Price stats
Beta
‪0.79‬
50-Day Avg
‪1.13‬
200-Day Avg
‪0.9542‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - BFRI - Biofrontera Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- BFRINASDAQBiofrontera Inc.15.62MMarket Cap+23.08%52-week change0.89P/E (Trailing)‪-25.65%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences Inc.15.55BMarket Cap+12.43%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.18P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+44.07%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.19BMarket Cap+47.82%52-week change37.31P/E (Trailing)‪5.04%‬Profit Margin
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
Profile Summary - BFRI - Biofrontera Inc.
About
Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products. Its primary aim is to address unmet needs in the treatment of skin diseases, with a particular emphasis on dermatology, represented by its flagship product, Ameluz. This prescription…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
